



35
7
7/11/03
RECEIVED
JUN 25 2003

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

TECH CENTER 1600/2900

Re application of: Melvyn LITTLE, et al.

Application Serial No. 09/424,705

Filed: June 2, 2000

For: **MUTATED OKT3 ANTIBODY**

Art Unit: 1644

Examiner: J. Roark

Confirmation No: 8422

Attorney's Docket No. 3528.0047.US00

RESPONSE TO OFFICE ACTION

Commissioner for Patents
P. O. Box 1450
Alexandria, VA 22313-1450

Sir:

This is a Response to the Office Action dated February 21, 2003. This response is submitted prior to or including the extended due date of **June 21, 2003**. A petition for a one (1) month extension of time and the requisite fee are enclosed herewith. If any further fees are required in order to maintain the pendency of the instant application, the Examiner is expressly authorized to charge such to Deposit Account No. 08-3038. The Examiner is respectfully requested to enter the amendments and reconsider the application.

AMENDMENTS TO THE SPECIFICATION

Please the following paragraphs as indicated:

The paragraph beginning at page 3, line 1:

7'
Therefore, the amplified DNA is inserted in a vector adapted for sequencing and for site specific mutagenesis, as well known to the person skilled in the art. For example, the vector pCR-Skript SK(+) sold by the company of Stratagene can be used. Mutations are inserted in the VH domain originating from OKT3 by site specific mutagenesis. The person skilled in the art is familiar with the conditions necessary for this purpose, they are also described e.g. in